Pulmonary drug delivery by powder aerosols

Journal of Controlled Release

Volumn 193, Issue , 2014, Pages 228-240

  Yang, Michael Yifei ^a   Chan, John Gar Yan ^a   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Dry powder formulation; Dry powder inhaler; Lung deposition; Pharmaceutical aerosol; Pulmonary drug delivery; SPECT imaging

Indexed keywords

DRY POWDER INHALER; DRY POWDERS; LUNG DEPOSITIONS; PHARMACEUTICAL AEROSOLS; PULMONARY DRUG DELIVERY; SPECT IMAGING;

INSULIN; AEROSOL; DRUG; POWDER;

AEROSOL; AIRWAY RESISTANCE; DENSITY; DISPERSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRY POWDER; DRY POWDER INHALER; HUMAN; METERED DOSE INHALER; OUTCOME ASSESSMENT; PARTICLE SIZE; PEAK INSPIRATORY FLOW; REVIEW; SPRAY DRYING; STATIC ELECTRICITY; SURFACE PROPERTY; ANIMAL; CHEMISTRY; DEVICES; DRUG EFFECTS; EQUIPMENT DESIGN; LUNG; METABOLISM; POWDER; PROCEDURES; TISSUE DISTRIBUTION;

AEROSOLS; ANIMALS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; INSULIN; LUNG; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDERS; STATIC ELECTRICITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84908279497     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.04.055     Document Type: Review

References (173)

1. H.-K. Chan Inhalation drug delivery devices and emerging technologies Expert Opin. Ther. Pat. 13 2003 1333 1343
2. W.H. Finlay The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction 2001 Academic Press San Diego; London
3. D.J. Ball, P.H. Hirst, S.P. Newman, B. Sonet, B. Streel, and F. Vanderbist Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device Int. J. Pharm. 245 2002 123 132
4. L. Borgstrom, E. Bondesson, F. Moren, E. Trofast, and S. Newman Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects Eur. Respir. J. 7 1994 69 73
5. G. Pitcairn, S. Reader, D. Pavia, and S. Newman Deposition of corticosteroid aerosol in the human lung by Respimat(r) Soft Mist(tm) inhaler compared to deposition by metered dose inhaler or by Turbuhaler(r) dry powder inhaler J. Aerosol Med. 18 2005 264 272
6. P.H. Hirst, R.E. Bacon, G.R. Pitcairn, M. Silvasti, and S.P. Newman A comparison of the lung deposition of budesonide from Easyhaler(r), Turbuhaler(r)and pMDI plus spacer in asthmatic patients Respir. Med. 95 2001 720 727
7. P.H. Hirst, S.P. Newman, D.A. Clark, and M.G.L. Hertog Lung deposition of budesonide from the novel dry powder inhaler AirmaxTM Respir. Med. 96 2002 389 396
8. L. Borgström, and S. Newman Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler(r) Int. J. Pharm. 97 1993 47 53
9. L. Borgström, S. Newman, A. Weisz, and F. Morén Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods J. Pharm. Sci. 81 1992 753 755
10. S.P. Newman, A. Hollingworth, and A.R. Clark Effect of different modes of inhalation on drug delivery from a dry powder inhaler Int. J. Pharm. 102 1994 127 132
11. G. Pitcairn, G. Lunghetti, P. Ventura, and S. Newman A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates Int. J. Pharm. 102 1994 11 18
12. S. Newman, G. Pitcairn, D. Adkin, M. Vidgren, and M. Silvasti Comparison of beclomethasone dipropionate delivery by Easyhaler(r) Dry Powder Inhaler and pMDI plus large volume spacer J. Aerosol Med. 14 2001 217 225
13. S. Warren, G. Taylor, J. Smith, H. Buck, and M. Parry-Billings Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique J. Aerosol Med. 15 2002 15 25
14. G. Pitcairn, J. Lim, A. Hollingworth, and S. Newman Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler J. Aerosol Med. 10 1997 295 306
15. M. Vidgren, A. Kärkkäinen, P. Karjalainen, P. Paronen, and J. Nuutinen Effect of powder inhaler design on drug deposition in the respiratory tract Int. J. Pharm. 42 1988 211 216
16. W. Glover, H.-K. Chan, S. Eberl, E. Daviskas, and J. Verschuer Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers Int. J. Pharm. 349 2008 314 322
17. G. Pitcairn, T. Lankinen, O.-P. Seppälä, and S. Newman Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort J. Aerosol Med. 13 2000 97 104
18. J.N. Pritchard The influence of lung deposition on clinical response J. Aerosol Med. 14 Suppl. 1 2001 S19 S26
19. B. Olsson, L. Borgstrom, H. Lundback, and M. Svensson Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products J. Aerosol Med. Pulm. Drug Deliv. 26 2013 355 369
20. B.Y. Shekunov, P. Chattopadhyay, H.H. Tong, and A.H. Chow Particle size analysis in pharmaceutics: principles, methods and applications Pharm. Res. 24 2007 203 227
21. L. Borgstrom, B. Olsson, and L. Thorsson Degree of throat deposition can explain the variability in lung deposition of inhaled drugs J. Aerosol Med. 19 2006 473 483
22. L. Borgstrom, L. Asking, and O. Beckman Dose variation, witin and between individuals, with different inhalation systems R.N. Dalby, P.R. Byron, S.J. Farr, Respiratory Drug Delivery V 1996 Interpharm Press Arizona, United States
23. P.T. Daley-Yates, D.A. Parkins, M.J. Thomas, B. Gillett, K.W. House, and H.G. Ortega Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products Clin. Ther. 31 2009 370 385
24. R.J. Theilmann, T.J. Arai, A. Samiee, D.J. Dubowitz, S.R. Hopkins, R.B. Buxton, and G.K. Prisk Quantitative MRI measurement of lung density must account for the change in T 2∗ with lung inflation J. Magn. Reson. Imaging 30 2009 527 534
25. D. Worlitzsch, R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K.C. Meyer, P. Birrer, G. Bellon, J. Berger, and T. Weiss Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients J. Clin. Investig. 109 2002 317 325
26. P. Zanen, L. Go, and J.-W. Lammers The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler Eur. J. Clin. Pharmacol. 54 1998 27 30
27. B.L. Laube, A.M. Edwards, R.N. Dalby, P.S. Creticos, and P.S. Norman The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma J. Allergy Clin. Immunol. 101 1998 475 483
28. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of β2-agonist particle size Am. J. Respir. Crit. Care Med. 172 2005 1497 1504
29. J.R. Carstairs, A.J. Nimmo, and P.J. Barnes Autoradiographic visualization of beta-adrenoceptor subtypes in human lung Am. Rev. Respir. Dis. 132 1985 541 547
30. W. De Backer, A. Devolder, G. Poli, D. Acerbi, R. Monno, C. Herpich, K. Sommerer, T. Meyer, and F. Mariotti Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients J. Aerosol Med. Pulm. Drug Deliv. 23 2010 137 148
31. E.M. Bakker, S. Volpi, E. Salonini, E.C. van der Wiel-Kooij, C.J.J.C.M. Sintnicolaas, W.C.J. Hop, B.M. Assael, P.J.F.M. Merkus, and H.A.W.M. Tiddens Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Eur. Respir. J. 38 2011 1328 1335
32. M. Gonzalez-Juarrero, and M.P. O'Sullivan Optimization of inhaled therapies for tuberculosis: the role of macrophages and dendritic cells Tuberculosis (Edinb.) 91 2011 86 92
33. P. Brand, T. Meyer, S. Haussermann, M. Schulte, G. Scheuch, T. Bernhard, B. Sommerauer, N. Weber, and M. Griese Optimum peripheral drug deposition in patients with cystic fibrosis J. Aerosol Med. 18 2005 45 54
34. S. Mukhopadhyay, G.E. Staddon, C. Eastman, M. Palmer, E.R. Davies, and F. Carswell The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis Respir. Med. 88 1994 203 211
35. S.P. Newman, and H.K. Chan In vitro/in vivo comparisons in pulmonary drug delivery J. Aerosol Med. Pulm. Drug Deliv. 21 2008 77 84
36. M.S. Coates, H.K. Chan, D.F. Fletcher, and J.A. Raper Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses Pharm. Res. 22 2005 1445 1453
37. S.P. Newman, I.R. Wilding, and P.H. Hirst Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int. J. Pharm. 208 2000 49 60
38. M.T. Vidgren, A. Kärkkäinen, T.P. Paronen, and P. Karjalainen Respiratory tract deposition of 99mTc-labelled drug particles administered via a dry powder inhaler Int. J. Pharm. 39 1987 101 105
39. M. Vidgren, A. Kärkkäinen, P. Karjalainen, and T. Paronen A novel labelling method for measuring the deposition of drug particles in the respiratory tract Int. J. Pharm. 37 1987 239 244
40. S. Devadason, M. Everard, C. MacEarlan, C. Roller, Q. Summers, P. Swift, L. Borgstrom, and P. Le Souef Lung deposition from the Turbuhaler in children with cystic fibrosis Eur. Respir. J. 10 1997 2023 2028
41. S. Newman, F. Moren, E. Trofast, N. Talaee, and S. Clarke Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler Eur. Respir. J. 2 1989 247 252
42. M. Biddiscombe, R. Melchor, V. Mak, R. Marriott, A. Taylor, M. Short, and S. Spiro The lung deposition of salbutamol, directly labelled with technetium-99 m, delivered by pressurised metered dose and dry powder inhalers Int. J. Pharm. 91 1993 111 121
43. H. Chrystyn Methods to identify drug deposition in the lungs following inhalation Br. J. Clin. Pharmacol. 51 2001 289 299
44. H. Möllmann, M. Wagner, B. Meibohm, G. Hochhaus, J. Barth, R. Stöckmann, M. Krieg, H. Weisser, C. Falcoz, and H. Derendorf Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration Eur. J. Clin. Pharmacol. 53 1998 459 467
45. S.P. Newman, G.R. Pitcairn, P.H. Hirst, and L. Rankin Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs Adv. Drug Deliv. Rev. 55 2003 851 867
46. J. Fleming, D.L. Bailey, H.-K. Chan, J. Conway, P.J. Kuehl, B.L. Laube, and S. Newman Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products J. Aerosol Med. Pulm. Drug Deliv. 25 Suppl. 1 2012 S29 S51
47. G.A. Digenis, E.P. Sandefer, R.C. Page, and W.J. Doll Gamma scintigraphy: an evolving technology in pharmaceutical formulation development - part 1 Pharm. Sci. Technol. Today 1 1998 100 108
48. S. Eberl, H.K. Chan, E. Daviskas, C. Constable, and I. Young Aerosol deposition and clearance measurement: a novel technique using dynamic SPET Eur. J. Nucl. Med. Mol. Imaging 28 2001 1365 1372
49. P.R. Phipps, I. Gonda, D.L. Bailey, P. Borham, G. Bautovich, and S.D. Anderson Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols Am. J. Respir. Crit. Care Med. 139 1989 1516 1523
50. H. Chan, P. Phipps, I. Gonda, P. Cook, R. Fulton, I. Young, and G. Bautovich Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract Eur. Respir. J. 7 1994 1483 1489
51. H.-K. CHAN Use of single photon emission computed tomography in aerosol studies J. Aerosol Med. 6 1993 23 36
52. J. Fleming, J. Conway, C. Majoral, L. Tossici-Bolt, I. Katz, G. Caillibotte, D. Perchet, M. Pichelin, B. Muellinger, and T. Martonen The use of combined single photon emission computed tomography and X-ray computed tomography to assess the fate of inhaled aerosol J. Aerosol Med. Pulm. Drug Deliv. 24 2011 49 60
53. S. Eberl, H.-K. Chan, and E. Daviskas SPECT imaging for radioaerosol deposition and clearance studies J. Aerosol Med. 19 2006 8 20
54. M.S.M. Berridge, Z.Z. Lee, and D.L.D. Heald Regional distribution and kinetics of inhaled pharmaceuticals Curr. Pharm. Des. 6 2000 1631 1651
55. S. Newman, and J. Fleming Challenges in assessing regional distribution of inhaled drug in the human lungs Expert Opin. Drug Deliv. 2011 1 15
56. J. Venegas, T. Winkler, and R.S. Harris Lung physiology and aerosol deposition imaged with positron emission tomography J. Aerosol Med. Pulm. Drug Deliv. 26 2013 1 8
57. M.F. Biddiscombe, S.N. Meah, S.R. Underwood, and O.S. Usmani Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition J. Aerosol Med. Pulm. Drug Deliv. 24 2011 165 173
58. J. Schroeter, J. Pritchard, D. Hwang, and T. Martonen Airway identification within planar gamma camera images using computer models of lung morphology Pharm. Res. 22 2005 1692 1699
59. J.S. Fleming, V. Sauret, J.H. Conway, and T.B. Martonen Validation of the conceptual anatomical model of the lung airway J. Aerosol Med. 17 2004 260 269
60. T.B. Martonen, J.D. Schroeter, and J.S. Fleming 3D in silico modeling of the human respiratory system for inhaled drug delivery and imaging analysis J. Pharm. Sci. 96 2007 603 617
61. S. Montesantos, J.S. Fleming, and L. Tossici-Bolt A spatial model of the human airway tree: the hybrid conceptual model J. Aerosol Med. Pulm. Drug Deliv. 23 2010 59 68
62. J.W. De Backer, W.G. Vos, S.C. Vinchurkar, R. Claes, A. Drollmann, D. Wulfrank, P.M. Parizel, P. Germonpré, and W. De Backer Validation of computational fluid dynamics in CT-based airway models with SPECT/CT Radiology 257 2010 854 862
63. J. Conway, J. Fleming, C. Majoral, I. Katz, D. Perchet, C. Peebles, L. Tossici-Bolt, L. Collier, G. Caillibotte, and M. Pichelin Controlled, parametric, individualized, 2-D and 3-D imaging measurements of aerosol deposition in the respiratory tract of healthy human subjects for model validation J. Aerosol Sci. 52 2012 1 17
64. T. Nilsson, C. Friberg, L. Kax, A. Niemi, S. Calander, Dry powder preparations for pre-metered dpi, in, Google Patents, 2005.
65. A.H. de Boer, H.K. Chan, and R. Price A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? Adv. Drug Deliv. Rev. 64 2012 257 274
66. C. Marriott, and H.W. Frijlink Lactose as a carrier for inhalation products: breathing new life into an old carrier Adv. Drug Deliv. Rev. 64 2012 217 219
67. J.G. Weers, J. Bell, H.K. Chan, D. Cipolla, C. Dunbar, A.J. Hickey, and I.J. Smith Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulm. Drug Deliv. 23 2010 5 23
68. W.H. Dehaan, J.C. Sung, D. Manzanedo, C. LAWLOR, M. Tauber, Inhalable dry powders, in, Google Patents, 2013.
69. H. Chrystyn The DiskusTM: a review of its position among dry powder inhaler devices Int. J. Clin. Pract. 61 2007 1022 1036
70. N. Islam, and M.J. Cleary Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - a review for multidisciplinary researchers Med. Eng. Phys. 34 2012 409 427
71. M.S. Coates, D.F. Fletcher, H.K. Chan, and J.A. Raper Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length J. Pharm. Sci. 93 2004 2863 2876
72. M.S. Coates, H.K. Chan, D.F. Fletcher, and J.A. Raper Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size J. Pharm. Sci. 95 2006 1382 1392
73. M.S. Coates, H.K. Chan, D.F. Fletcher, and H. Chiou Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler Pharm. Res. 24 2007 1450 1456
74. Z.B. Tong, B. Zheng, R.Y. Yang, A.B. Yu, and H.K. Chan CFD-DEM investigation of the dispersion mechanisms in commercial dry powder inhalers Powder Technol. 240 2013 19 24
75. Z.B. Tong, R.Y. Yang, A.B. Yu, S. Adi, and H.K. Chan Numerical modelling of the breakage of loose agglomerates of fine particles Powder Technol. 196 2009 213 221
76. Z.B. Tong, S. Adi, R.Y. Yang, H.K. Chan, and A.B. Yu Numerical investigation of the de-agglomeration mechanisms of fine powders on mechanical impaction J. Aerosol Sci. 42 2011 811 819
77. Z. Tong, R. Yang, K. Chu, A. Yu, S. Adi, and H. Chan Numerical study of the effects of particle size and polydispersity on the agglomerate dispersion in a cyclonic flow Chem. Eng. J. 164 2010 432 441
78. J. Shur, S. Lee, W. Adams, R. Lionberger, J. Tibbatts, and R. Price Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers AAPS J. 14 2012 667 676
79. J. Gac, T.R. Sosnowski, and L. Gradoń Turbulent flow energy for aerosolization of powder particles J. Aerosol Sci. 39 2008 113 126
80. K.L. Zeman, J. Wu, and W.D. Bennett Targeting aerosolized drugs to the conducting airways using very large particles and extremely slow inhalations J. Aerosol Med. Pulm. Drug Deliv. 23 2010 363 369
81. G. Martin, C. Marriott, and X.-M. Zeng Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations Pharm. Res. 24 2007 361 369
82. A.H. de Boer, G.K. Bolhuis, D. Gjaltema, and P. Hagedoorn Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler Int. J. Pharm. 153 1997 67 77
83. W. Glover, H.-K. Chan, S. Eberl, E. Daviskas, and S. Anderson Lung deposition of mannitol powder aerosol in healthy subjects J. Aerosol Med. 19 2006 522 532
84. M. DeLong, J. Wright, M. Dawson, T. Meyer, K. Sommerer, and C. Dunbar Dose delivery characteristics of the AIR(r) pulmonary delivery system over a range of inspiratory flow rates J. Aerosol Med. 18 2005 452 459
85. A. Clark, and A. Hollingworth The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing J. Aerosol Med. 6 1993 99 110
86. W.E. Kamin, T. Genz, S. Roeder, G. Scheuch, R. Cloes, R. Juenemann, and T. Trammer The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient J. Aerosol Med. 16 2003 21 29
87. A.H. de Boer, H.M.I. Winter, and C.F. Lerk Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance Int. J. Pharm. 130 1996 231 244
88. W. Janssens, P. VandenBrande, E. Hardeman, E. De Langhe, T. Philps, T. Troosters, and M. Decramer Inspiratory flow rates at different levels of resistance in elderly COPD patients Eur. Respir. J. 31 2008 78 83
89. T. Ehtezazi, M.A. Horsfield, P.W. Barry, P. Goodenough, and C. O'Callaghan Effect of device inhalational resistance on the three dimensional configuration of the upper airway J. Pharm. Sci. 94 2005 1418 1426
90. D.W. McRobbie, and S.E. Pritchard Studies of the human oropharyngeal airspaces using magnetic resonance imaging. III. The effects of device resistance with forced maneuver and tidal breathing on upper airway geometry J. Aerosol Med. 18 2005 325 336
91. K. Svartengren, P. Lindestad, M. Svartengren, K. Philipson, G. Bylin, and P. Camner Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics Am. J. Respir. Crit. Care Med. 152 1995 32 37
92. B. Grgic, W.H. Finlay, P.K.P. Burnell, and A.F. Heenan In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries J. Aerosol Sci. 35 2004 1025 1040
93. H.A. Tiddens, D.E. Geller, P. Challoner, R.J. Speirs, K.C. Kesser, S.E. Overbeek, D. Humble, S.B. Shrewsbury, and T.A. Standaert Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older J. Aerosol Med. 19 2006 456 465
94. P.S. Sarinas, T.E. Robinson, A.R. Clark, J. Canfield, R.K. Chitkara, and R.B. Fick Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases CHEST J. 114 1998 988 992
95. M.H. Dewar, A. Jamieson, A. McLean, and G.K. Crompton Peak inspiratory flow through turbuhaler(r) in chronic obstructive airways disease Respir. Med. 93 1999 342 344
96. S.P. Newman, F. Morén, E. Trofast, N. Talaee, and S.W. Clarke Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy Int. J. Pharm. 74 1991 209 213
97. A.C. Raimondi, J. Schottlender, D. Lombardi, and N.A. Molfino Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder CHEST J. 112 1997 24 28
98. I. Amirav, M.T. Newhouse, and Y. Mansour Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma Pediatr. Pulmonol. 39 2005 447 451
99. C. Vogelberg, H.-J. Kremer, B. Ellers-Lenz, M. Engel, J. Maus, F. Conrad, and R. Hermann Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer(r) Respir. Med. 98 2004 924 931
100. M. Parry Billings, C. Birrell, L. Oldham, and C. O'Callaghan Inspiratory flow rate through a dry powder inhaler (Clickhaler(r)) in children with asthma Pediatr. Pulmonol. 35 2003 220 226
101. W.C. Hinds Aerosol technology: properties, behavior, and measurement of airborne particles William C. Hinds, 2nd ed. 1999 Wiley New York
102. W. Stahlhofen, G. Rudolf, and A. James Intercomparison of experimental regional aerosol deposition data J. Aerosol Med. 2 1989 285 308
103. A.A. Rostami Computational modeling of aerosol deposition in respiratory tract: a review Inhal. Toxicol. 21 2009 262 290
104. R.J. Malcolmson, and J.K. Embleton Dry powder formulations for pulmonary delivery Pharm. Sci. and Technol. Today 1 1998 394 398
105. J. Haughney, D. Price, N.C. Barnes, J.C. Virchow, N. Roche, and H. Chrystyn Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs Respir. Med. CME 3 2010 125 131
106. T.C. Carvalho, J.I. Peters, and R.O. Williams Iii Influence of particle size on regional lung deposition - what evidence is there? Int. J. Pharm. 406 2011 1 10
107. C. Bosquillon, C. Lombry, V. Préat, and R. Vanbever Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance J. Control. Release 70 2001 329 339
108. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 1997 1868 1872
109. F.J. Ahmad, G. Mittal, G.K. Jain, G. Malhotra, R.K. Khar, and A. Bhatnagar Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions Eur. J. Pharm. Biopharm. 71 2009 282 291
110. Pulmonary delivery of nanosized alendronate for decorporation of inhaled heavy metals: formulation development, characterization and gamma scintigraphic evaluation Pharm. Dev. Technol. 2013 1 11
111. H.-K. Chan, and I. Gonda Aerodynamic properties of elongated particles of cromoglycic acid J. Aerosol Sci. 20 1989 157 168
112. H.-K. Chan, and I. Gonda Physicochemical characterization of a new respirable form of nedocromil J. Pharm. Sci. 84 1995 692 696
113. A.R. Martin, and W.H. Finlay Enhanced deposition of high aspect ratio aerosols in small airway bifurcations using magnetic field alignment J. Aerosol Sci. 39 2008 679 690
114. D. Johnson, N. Esmen, K. Carlson, T. Pearce, and B. Thomas Aerodynamic behavior of lipid microtubule aerosols J. Aerosol Sci. 31 2000 181 188
115. M. Lippmann Effects of fiber characteristics on lung deposition, retention, and disease Environ. Health Perspect. 88 1990 311
116. N.Y. Chew, and H.-K. Chan Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols Pharm. Res. 16 1999 1098 1103
117. S. Duddu, S. Sisk, Y. Walter, T. Tarara, K. Trimble, A. Clark, M. Eldon, R. Elton, M. Pickford, P. Hirst, S. Newman, and J. Weers Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere(r) powder Pharm. Res. 19 2002 689 695
118. R. Vehring Pharmaceutical particle engineering via spray drying Pharm. Res. 25 2008 999 1022
119. H. Adi, D. Traini, H.K. Chan, and P.M. Young The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations J. Pharm. Sci. 97 2008 2780 2788
120. N.K. Chew, and H.-K. Chan Use of solid corrugated particles to enhance powder aerosol performance Pharm. Res. 18 2001 1570 1577
121. N.Y. Chew, P. Tang, H.-K. Chan, and J.A. Raper How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm. Res. 22 2005 148 152
122. S. Adi, H. Adi, P. Tang, D. Traini, H.-k. Chan, and P.M. Young Micro-particle corrugation, adhesion and inhalation aerosol efficiency Eur. J. Pharm. Sci. 35 2008 12 18
123. D. Heng, P. Tang, J. Cairney, H.-K. Chan, R. Salama, and D. Cutler Focused-ion-beam milling: a novel approach to probing the interior of particles used for inhalation aerosols Pharm. Res. 24 2007 1608 1617
124. P. Kwok, A. Tunsirikongkon, W. Glover, and H.-K. Chan Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery Pharm. Res. 28 2011 788 796
125. Q.T. Zhou, L. Qu, I. Larson, P.J. Stewart, and D.A.V. Morton Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach Int. J. Pharm. 394 2010 50 59
126. W. Balachandran, W. Machowski, E. Gaura, and C. Hudson Control of drug aerosol in human airways using electrostatic forces J. Electrost. 40-41 1997 579 584
127. P.R. Byron, J. Peart, and J.N. Staniforth Aerosol electrostatics I: properties of fine powders before and after aerosolization by dry powder inhalers Pharm. Res. 14 1997 698 705
128. J. Wong, H.-K. Chan, and P.C.L. Kwok Electrostatics in pharmaceutical aerosols for inhalation Ther. Deliv. 4 2013 981 1002
129. N.Y.K. Chew, D.F. Bagster, and H.-K. Chan Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders Int. J. Pharm. 206 2000 75 83
130. N.Y.K. Chew, H.-K. Chan, D.F. Bagster, and J. Mukhraiya Characterization of pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of capsule device configuration J. Aerosol Sci. 33 2002 999 1008
131. N. Chew, and H.-K. Chan Effect of powder polydispersity on aerosol generation J. Pharm. Pharm. Sci. 5 2002 153 159
132. P. Tang, N.Y.K. Chew, H.-K. Chan, and J.A. Raper Limitation of determination of surface fractal dimension using N2 absorption isotherms and modified Frenkel-Halsey-Hill theory Langmuir 19 2003 2632 2638
133. P. Tang, H.-K. Chan, E. Tam, N. de Gruyter, and J. Chan Preparation of NaCl powder suitable for inhalation Ind. Eng. Chem. Res. 45 2006 4188 4192
134. H.-K. Chan, A.R. Clark, I. Gonda, M. Mumenthaler, and C. Hsu Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery Pharm. Res. 14 1997 431 437
135. H.-K. Chan, and P.C.L. Kwok Production methods for nanodrug particles using the bottom-up approach Adv. Drug Deliv. Rev. 63 2011 406 416
136. S.H. Lee, D. Heng, W.K. Ng, H.-K. Chan, and R.B.H. Tan Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy Int. J. Pharm. 403 2011 192 200
137. S. D'Addio, J. Chan, P. Kwok, B. Benson, R. Prud'homme, and H.-K. Chan Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying Pharm. Res. 30 2013 2891 2901
138. S.M. D'Addio, J.G.Y. Chan, P.C.L. Kwok, R.K. Prud'homme, and H.-K. Chan Constant size, variable density aerosol particles by ultrasonic spray freeze drying Int. J. Pharm. 427 2012 185 191
139. B.K. Johnson, and R.K. Prud'homme Chemical processing and micromixing in confined impinging jets, American Institute of Chemical Engineers AIChE J 49 2003 2264 2282
140. H. Chiou, H.-K. Chan, R. Prud'homme, and J.A. Raper Evaluation on the use of confined liquid impinging jets for synthesis of nano-drug particles Drug Dev. Ind. Pharm. 34 2008 59 64
141. H. Chiou, H.-K. Chan, R. Prud'homme, and J.A. Raper A novel production method for inhalable cyclosporin A powders by confined liquid impinging jet precipitation J. Aerosol Sci. 39 2008 500 509
142. R. Bustami, H.-K. Chan, F. Dehghani, and N.R. Foster Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide Pharm. Res. 17 2000 1360 1366
143. R. Bustami, H.-K. Chan, T. Sweeney, F. Dehghani, and N. Foster Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system Pharm. Res. 20 2003 2028 2035
144. R.T. Bustami, H.-K. Chan, F. Dehghani, and N.R. Foster Recent application of supercritical fluid technology to pharmaceutical powder systems, Kona, powder and particle 19 2001 57 70 (invited review)
145. A. Abbas, M. Srour, P. Tang, H. Chiou, H.-K. Chan, and J.A. Romagnoli Sonocrystallisation of sodium chloride particles for inhalation Chem. Eng. Sci. 62 2007 2445 2453
146. Y. Liu, C. Cheng, R.K. Prud'homme, and R.O. Fox Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation Chem. Eng. Sci. 63 2008 2829 2842
147. J.-F. Chen, Y.-H. Wang, F. Guo, X.-M. Wang, and C. Zheng Synthesis of nanoparticles with novel technology: high-gravity reactive precipitation Ind. Eng. Chem. Res. 39 2000 948 954
148. M. Gänsslen Über inhalation von insulin J. Mol. Med. 4 1925 2342 2343
149. F.M. Wigley, J.H. Londono, S.H. Wood, J.C. Shipp, and R.H. Waldman Insulin across respiratory mucosae by aerosol delivery Diabetes 20 1971 552 556
150. J.S. Patton Mechanisms of macromolecule absorption by the lungs Adv. Drug Deliv. Rev. 19 1996 3 36
151. J.S. Patton, and P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74
152. S. White, D.B. Bennett, S. Cheu, P.W. Conley, D.B. Guzek, S. Gray, J. Howard, R. Malcolmson, J.M. Parker, and P. Roberts EXUBERA(r): pharmaceutical development of a novel product for pulmonary delivery of insulin Diabetes Technol. Ther. 7 2005 896 906
153. T. Heise, A. Brugger, C. Cook, U. Eckers, A. Hutchcraft, L. Nosek, K. Rave, J. Troeger, P. Valaitis, S. White, and L. Heinemann PROMAXX(r) inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler Diabetes Obes. Metab. 11 2009 455 459
154. M. Corporation FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes 2014
155. A. Pfützner, and T. Forst Pulmonary insulin delivery by means of the Technosphere(tm) drug carrier mechanism Expert Opin. Drug Deliv. 2 2005 1097 1106
156. G.S. Mack Pfizer dumps Exubera Nat. Biotechnol. 25 2007 1331 1332
157. J. Kling Dreamboat sinks prospects for fast approval of inhaled insulin Nat. Biotechnol. 29 2011 175 176
158. J. Chan, A. Tyne, A. Pang, H.-K. Chan, P. Young, W. Britton, C. Duke, and D. Traini A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection Pharm. Res. 2013 1 15
159. E.M. Westerman, A.H. De Boer, P.P.H. Le Brun, D.J. Touw, A.C. Roldaan, H.W. Frijlink, and H.G.M. Heijerman Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study J. Cyst. Fibros. 6 2007 284 292
160. F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann Pharmacokinetics of inhaled colistin in patients with cystic fibrosis J. Antimicrob. Chemother. 57 2006 306 311
161. L.R. Cass, J. Brown, M. Pickford, S. Fayinka, S. Newman, C. Johansson, and A. Bye Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers Clin. Pharmacokinet. 36 1999 21 31
162. T. Corcoran Inhaled delivery of aerosolized cyclosporine Adv. Drug Deliv. Rev. 58 2006 1119 1127
163. S.A. Meenach, K.W. Anderson, J. Zach Hilt, R.C. McGarry, and H.M. Mansour Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer Eur. J. Pharm. Sci. 49 2013 699 711
164. N. Wauthoz, P. Deleuze, A. Saumet, C. Duret, R. Kiss, and K. Amighi Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment Pharm. Res. 28 2011 762 775
165. W. Liang, P.C. Kwok, M.Y. Chow, P. Tang, A. James Mason, H.-K. Chan, and J.K. Lam Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids Eur. J. Pharm. Biopharm. 86 2013 64 73
166. A.S. Tyne, J.G.Y. Chan, E.R. Shanahan, I. Atmosukarto, H.-K. Chan, W.J. Britton, and N.P. West TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines Vaccine 31 2013 4322 4329
167. W.H. Roa, S. Azarmi, M.H.D.K. Al-Hallak, W.H. Finlay, A.M. Magliocco, and R. Löbenberg Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model J. Control. Release 150 2011 49 55
168. P. Tappenden, S. Harnan, L. Uttley, M. Mildred, C. Carroll, and A. Cantrell Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model Health Technol. Assess. 17 2013 1 182
169. D. Cipolla, I. Gonda, and H.-K. Chan Liposomal formulations for inhalation Ther. Deliv. 4 2013 1047 1072
170. F. Andrade, D. Rafael, M. Videira, D. Ferreira, A. Sosnik, and B. Sarmento Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases Adv. Drug Deliv. Rev. 65 2013 1816 1827
171. W. Yang, J.I. Peters, and R.O. Williams III Inhaled nanoparticles - a current review Int. J. Pharm. 356 2008 239 247
172. S.M. Ametamey, M. Honer, and P.A. Schubiger Molecular imaging with PET Chem. Rev. 108 2008 1501 1516
173. M. Rudin, and R. Weissleder Molecular imaging in drug discovery and development Nat. Rev. Drug Discov. 2 2003 123 131]